Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147677 | 0.79 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL11053483 | 0.79 | MEN1 (0.51) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL10147411 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1POLBNLRP3KMT2A | |
| SCHEMBL7523545 | 0.78 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1NLRP3KMT2AMEN1 | |
| Phosphine SCHEMBL27473852 | 0.77 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1NLRP3KMT2AMEN1 | |
| SCHEMBL22062257 | 0.75 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1NLRP3KMT2AMEN1 | |
| SCHEMBL7642742 | 0.75 | CTDSP1 (0.44) | SMN1; SMN2ALDH1A1POLBNLRP3KMT2A | |
| SCHEMBL28184684 | 0.74 | NLRP3 (0.46) | SMN1; SMN2ALDH1A1NLRP3KMT2AMEN1 | |
| SCHEMBL2911004 | 0.74 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL4320007 | 0.74 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548509-B2 | For diagnosis and therapy of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety | NEUROGEN CORPORATION | 2003-04-15 | — | — | US | disclosed |
| EP-0960110-B8 | 3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020058668-A1 | 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands | YUAN JUN (US) | 2002-05-16 | — | — | US | disclosed |
| EP-0960110-B1 | 3-ARYL SUBSTITUTED PYRAZOLO 4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF 1?) SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6211187-B1 | POST-TRAUMATIC STRESS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | NEUROGEN CORPORATION | 2001-04-03 | — | — | US | disclosed |
| EP-0960110-A1 | 3-ARYL SUBSTITUTED PYRAZOLO 4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF 1?) SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998029413-A1 | 3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5723608-A | 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands | NEUROGEN CORPORATION (US) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058668-A1 | 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands | CRH, CRHR1, CRHR2 | SMN1; SMN2 4380/4885ALDH1A1 2171/4885POLB 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.